ClinicalTrials.gg
CompletedNCT02254434Updated Nov 13, 2017

A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions

A Phase 1 interventional study of Eltrombopag in Cirrhosis, Liver, sponsored by GlaxoSmithKline. Completed at 1 site in Mexico. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-13.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Liver Cirrhosis with a site in Mexico — 4 open to participants now, 4 under way, 1 of them phase 3. Liver Cirrhosis · Mexico.

Enrollment
18th of 21
26 · median 68
Started
2014
with 1 other
Phase 1
Only one
of the 31
Registered
15th of 31
by date

Among the 31 studies in Liver Cirrhosis with a site in Mexico, this one is the 18th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2014, is the only one in phase 1, and was the 15th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

4 of the 31 studies in Liver Cirrhosis with a site in Mexico are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Liver Cirrhosis with a site in Mexico, or all of them as a file.
02

Study summary

This study evaluates pharmacokinetics of eltrombopag 50 mg after the oral administration in Mexican healthy volunteers under fasting conditions. The study will be an open label, single dose study with 26 subjects planned to be enrolled. Healthy subjects (male and female) aged between 18 - 50 years of age (inclusive) and a Body Mass Index within the range of 18-27.0 kg/meter (m)\^2 (inclusive) were enrolled according to Quetelet. REVOLADE is a registered trademark of the GSK group of companies.

03

Conditions studied

  • Cirrhosis, Liver

Keywords

  • eltrombopag 50 mg
  • healthy volunteers
  • pharmacokinetic
  • single-dose
  • Open-label
  • fasting
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects' participation must be voluntary according to the General Health Law and an form must be obtained for each subject before their participation. Compliance to Helsinki´s Declaration, its Japan Review and good clinical practice (GCP) should be followed.
  • Mexican male and female healthy volunteers with 18 to 50 years old will be included. A female subject is eligible to participate if she is of, Non- defined as pre menopausal females with a documented tubal ligation or hysterectomy (for this definition, "documented" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records]; or defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] > 40 milliinternational units per milliliter (MlU/ml) and estradiol \< 40 picogram per milliliter [pg/ml] [\<147 picomole per liter (pmol/L)] is confirmatory). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the methods as described by the Investigator/designee, if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method). Child-bearing potential with negative pregnancy test as determined by (serum or urine) human chorionic gonadotropin (hCG) test at screening or prior to dosing abbr de ante meridiem (AN ). Agrees to use one of the contraception methods listed by Investigator/designee for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until seven days after the drug administration. or has only same-sex partners, when this is her preferred and usual lifestyle.
  • (BMI) between 18-27.0 kilogram per meter (kg/m\^2) according to Quetelet.
  • Volunteers should be healthy as determined by their medical evaluation done by the physicians in the center and by their safety labs results done at a certified local laboratory.
  • Variation limits within normal ranges on their screening visit are: Blood pressure (BP) (seating) between 90 and 130 millimeters of mercury (mm Hg) for Systolic pressure and between 60 and 90 mmHg diastolic pressure, heart rate (HR) between 55 and 100 beats per minute (bpm) and respiratory rate (RR) between 14 and 20 per minute.
  • Safety laboratory tests to be done include: Hematology: Complete blood count with differential, , Hematocrit, count, etc; Blood chemistry: Albumin, Alkaline phosphatase, aspartate-aminotransferase (), alanine aminotransferase (ALT), Urea, Calcium, Chloride, Glucose, Phosphate, Potassium, Serum creatinine, Sodium, Total , Total protein, etc; Urinalysis: pH, Specific gravity, Protein, Glucose, Ketones, Bilirubin, Occult blood and cells, Nitrite, Urobilinogen, Leukocytes, Microscopic examination; and C tests; (HIV) test; Serum pregnancy test; Drug abuse test; Alcohol detection test; Urine Pregnancy test; ; Chest X ray. Normal variation limits for laboratory values will be +/- 10% from normal range, unless the principal investigator (PI) considers another deviation as clinically non-significant. In that case, values should be documented in the volunteer's clinical file as well as the decision to include the subject prior consult with GlaxoSmithKline (GSK) Medical Monitor. For safety reasons and as per the PI criteria additional ECG or safety labs may be performed.

Exclusion criteria

Exclusion Criteria:

  • Subjects with changes on their vital signs compared to what obtained in the screening visit.
  • Volunteers that not comply with all the inclusion criteria described previously
  • Volunteers with history of cardiovascular, renal, hepatic, muscular, metabolic. Clinically relevant hematologic, gastrointestinal, neurological, endocrine, pulmonary, mental disease or any other organical abnormality. Volunteers with muscular traumatism within 21 days before the study.
  • Volunteers that require any drug during the study, besides the study drug.
  • Volunteers with dyspepsia, gastritis, esofagitis, duodenal o gastric ulcers.
  • Volunteers that have received hepatic metabolism drug inhibitors or inducers within 30 days of the beginning of the study and that have received drugs that may alter urinary pH, like antiacids with sodium bicarbonate, potasium citrate and certain diuretics
  • Volunteers who received any drug and that 7 half lives have not been completed at the beginning of the study.
  • Volunteers who have , alkaline phosphatase and \<= 1.5x (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • interval duration (QTc) values of triplicate ECGs obtained over a brief recording period: QTc \< 450 milliseconds (msec); or QTc \< 480 msec in subjects with Bundle Branch Block.
  • Volunteers that might have required to be hospitalized for any reason within 6 months before the beginning of the study
  • Subjects with a previous participation in another research study within 60 days prior to the beginning of the study.
  • Subjects allergic to any food, drug and/or substance
  • Subjects with known history of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Subjects who consume alcohol, coffee, grapefruit, nicotine, orange or metilxantines containing substances (coffee, tea, chocolate, cola products, broiled products etc) within 72 hours prior to their confinement period and until the end of the study.
  • Subjects that might have lost or donated 450 ml of blood within the 60 days prior to the beginning of the study.
  • Alcohol or drug abuse history
  • Volunteers who require special meals (vegetarian).
  • Unwillingness or unable to understand the nature, objectives of possible consequences of the study.
  • Evidence of not being able to cooperate during the study
  • Positive alcohol, drug abuse and/or pregnancy tests
  • Breast feeding
  • Volunteers under any kind of hormonal therapy
  • Volunteers not registered at COFEPRIS web page
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Eltrombopag 50 mg

    Each volunteer will receive orally, single dose of tablet eltrombopag 50 mg under fasting conditions

    Drug: Eltrombopag

Interventions

  • Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally

06

What researchers measure

Primary outcomes

  1. Composite of PK parameters for eltrombopag

    Following PK parameters will be assessed: Area under the concentration-time curve from time zero to last time of quantifiable concentration within a subject (AUC\[0-t\]), area under the curve (concentration/time) from time 0 extrapolated to infinity (AUC\[0 inf\]), maximum observed concentration (Cmax) and time to Cmax (tmax)

    Time frame: Serum Pharmacokinetic (PK) samples will be collected pre-dose and then samples will be obtained 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12, 16, 24, 48, 72 and 96 hours after drug administration

Secondary outcomes

  1. Incidence and nature of adverse events (AEs) and Serious adverse events (SAEs)

    AEs and SAEs will be collected from the screening until the follow-up visit

    Time frame: Up to Day 12

  2. Monitoring vital signs

    Vital signs assessments included temperature, systolic and diastolic blood pressure, and pulse rate measurements

    Time frame: Up to Day 12

  3. Electrocardiograms (ECG) assessments

    Single 12-lead ECGs will be obtained over a brief (eg, 5-10 minute) recording period at each study visit.

    Time frame: Up to Day 12

  4. Clinical laboratory parameters

    Clinical laboratory parameters will include hematology, clinical chemistry and urine analysis

    Time frame: Up to Day 12

07

Study locations

1 site
  • GSK Investigational Site
    Mexico City, 14610, Mexico
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Sep 2014, 0 months.

Of 32 phase 1 interventional studies under Liver Cirrhosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 29. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2014
First posted
Oct 1, 2014
StartActual
Aug 28, 2014
Primary completionActual
Sep 8, 2014
CompletionActual
Sep 8, 2014
Last update
Nov 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02254434
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 1, 2014
Start date
Aug 28, 2014
Primary completion
Sep 8, 2014
Completion
Sep 8, 2014
Last update
Nov 13, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion